Supplier
ST. Charles Hospital and Rehabilitation Center
ST. Charles Hospital and Rehabilitation Center was paid $15.46M by Medicaid between Jan 2018 and Dec 2024, across 166 billing codes. Its largest line is 97110, Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion — 21% of everything it billed.
33Billing provider infoST. CHARLES HOSPITAL AND REHABILITATION CENTER
PORT JEFFERSON, NY 11714
PORT JEFFERSON, NY 11714
33aNPI1164481529assigned 03/22/2006
33bProvider typeCommunity/Retail Pharmacy
28Total paid$15.46M
24GClaims355,365
24DCodes billed166
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Community/Retail Pharmacy providers in New York
Rank by total paid#2 of 129
Median peer was paid$2K
This provider vs. median7,588×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 2,924 | $87K | |
| 2019 | 21,411 | $845K | |
| 2020 | 47,197 | $1.93M | |
| 2021 | 67,829 | $2.94M | |
| 2022 | 72,451 | $3.18M | |
| 2023 | 77,865 | $3.56M | |
| 2024incomplete | 65,688 | $2.93M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 21% | 56,402 | 14,590 | $3.17M |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | 9.8% | 47,547 | 12,972 | $1.52M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 6.6% | 6,387 | 6,157 | $1.01M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 5.3% | 5,273 | 5,100 | $825K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | 5.2% | 1,103 | 1,097 | $798K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | 5.1% | 6,413 | 5,923 | $785K |
| D0120 | Dental checkup, returning patientPeriodic oral evaluation - established patient | 3.9% | 12,144 | 5,613 | $608K |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | 3.7% | 18,627 | 6,138 | $566K |
| 96361 | Intravenous infusion, hydration; each additional hour | 3.5% | 2,677 | 2,458 | $539K |
| G0378 | Hospital observation service, per hour | 2.9% | 1,116 | 1,069 | $448K |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 2.8% | 2,934 | 2,843 | $439K |
| 97161 | 2.3% | 3,544 | 3,513 | $362K |
154 more codes
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | 1.5% | 2,520 | $228K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | 1.4% | 1,331 | $215K |
| 95810 | Polysomnography; sleep staging with 4 or more additional parameters | 1.3% | 272 | $208K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 1.3% | 1,751 | $200K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 1.3% | 2,720 | $199K |
| 97162 | 1.2% | 1,554 | $191K | |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 1.2% | 1,124 | $187K |
| 70450 | Computed tomography, head or brain; without contrast material | 1.1% | 786 | $172K |
| D1110 | Prophylaxis - adult | 1.0% | 3,261 | $162K |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | 1.0% | 4,009 | $162K |
| 80053 | Comprehensive metabolic panel | 1.0% | 9,256 | $156K |
| 97116 | 1.0% | 3,858 | $156K | |
| D0274 | Bitewings - four radiographic images | <1% | 3,786 | $150K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 4,444 | $142K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | <1% | 625 | $140K |
| 93975 | <1% | 329 | $120K | |
| 99202 | Office or other outpatient visit for the evaluation and management of a new patient, straightforward | <1% | 892 | $112K |
| D7140 | Extraction, erupted tooth or exposed root | <1% | 1,196 | $111K |
| D2392 | Resin-based composite - two surfaces, posterior, primary or permanent | <1% | 977 | $86K |
| 92557 | <1% | 1,387 | $84K | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 1,766 | $82K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 324 | $69K |
| D2391 | Resin-based composite - one surface, posterior, primary or permanent | <1% | 843 | $67K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 405 | $63K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 2,649 | $62K |
| D0150 | Comprehensive oral evaluation - new or established patient | <1% | 1,355 | $60K |
| 0202U | Oncology (prostate), multianalyte, gene expression profiling | <1% | 1,479 | $53K |
| 36415 | Collection of venous blood by venipuncture | <1% | 12,444 | $52K |
| D0210 | Intraoral - complete series of radiographic images | <1% | 1,090 | $49K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 1,636 | $42K |
| J0585 | Injection, onabotulinumtoxina, 1 unit | <1% | 324 | $42K |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 109 | $41K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 2,078 | $32K |
| D0140 | Limited oral evaluation - problem focused | <1% | 909 | $32K |
| D0220 | Intraoral - periapical first radiographic image | <1% | 1,647 | $28K |
| 86850 | <1% | 1,685 | $27K | |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 152 | $24K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 2,135 | $22K |
| 86900 | <1% | 1,700 | $20K | |
| D0230 | Intraoral - periapical each additional radiographic image | <1% | 873 | $20K |
| 86901 | <1% | 1,701 | $20K | |
| 85610 | <1% | 5,610 | $19K | |
| 90791 | Psychiatric diagnostic evaluation | <1% | 108 | $19K |
| M0245 | Intravenous infusion, bamlanivimab and etesevimab, includes infusion and post administration monitoring | <1% | 67 | $13K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 4,724 | $13K |
| D2331 | <1% | 127 | $13K | |
| 83880 | <1% | 458 | $11K | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 1,920 | $11K |
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r | <1% | 152 | $11K |
| 87631 | <1% | 227 | $11K | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 549 | $11K |
| D0160 | <1% | 178 | $10K | |
| 81025 | <1% | 3,766 | $10K | |
| J3490 | Unclassified drugs | <1% | 1,336 | $9K |
| 97166 | <1% | 84 | $9K | |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 8,280 | $8K |
| 84702 | <1% | 1,385 | $8K | |
| 85730 | <1% | 5,511 | $7K | |
| 45378 | Colonoscopy, flexible; diagnostic, including collection of specimen(s) | <1% | 12 | $7K |
| 97165 | <1% | 68 | $6K | |
| T1017 | Case management, billed per 15 minutes | <1% | 264 | $6K |
| M0243 | Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring | <1% | 19 | $6K |
| D0330 | Panoramic radiographic image | <1% | 115 | $6K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 1,574 | $5K |
| 88342 | <1% | 79 | $5K | |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 2,979 | $4K |
| 95806 | <1% | 52 | $4K | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 924 | $3K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 74 | $3K |
| D4341 | <1% | 31 | $3K | |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | <1% | 3,327 | $3K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 554 | $3K |
| D1208 | Topical application of fluoride, excluding varnish | <1% | 227 | $3K |
| 80061 | Lipid panel | <1% | 314 | $3K |
| 92567 | <1% | 195 | $2K | |
| 80076 | <1% | 286 | $2K | |
| 87088 | <1% | 2,351 | $2K | |
| M0222 | Intravenous injection, bebtelovimab, includes injection and post administration monitoring | <1% | 18 | $2K |
| D2160 | <1% | 16 | $2K | |
| D9110 | <1% | 55 | $2K | |
| D2330 | <1% | 20 | $2K | |
| 82375 | <1% | 161 | $2K | |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 95 | $2K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 544 | $2K |
| 80050 | General health panel | <1% | 64 | $1K |
| 82746 | <1% | 1,708 | $1K | |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 157 | $1K |
| 88304 | <1% | 70 | $1K | |
| 85027 | <1% | 2,562 | $1K | |
| 82947 | <1% | 1,451 | $1K | |
| 96367 | <1% | 30 | $1K | |
| 97802 | <1% | 12 | $1K | |
| S0028 | Injection, famotidine, 20 mg | <1% | 93 | $909.81 |
| 81003 | <1% | 3,439 | $908.35 | |
| 71046 | Radiologic examination, chest; 2 views | <1% | 169 | $849.98 |
| 71045 | Radiologic examination, chest; single view | <1% | 1,686 | $749.64 |
| 83735 | <1% | 5,205 | $644.26 | |
| C1889 | Implantable/insertable device, not otherwise classified | <1% | 60 | $535.79 |
| J2704 | Injection, propofol, 10 mg | <1% | 4,063 | $417.60 |
| 83690 | <1% | 2,018 | $340.43 | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 12 | $321.08 |
| 84100 | <1% | 3,983 | $313.95 | |
| 86141 | <1% | 1,754 | $277.70 | |
| 82550 | <1% | 2,166 | $254.02 | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 3,505 | $252.84 |
| 87081 | <1% | 237 | $241.53 | |
| 82077 | <1% | 1,283 | $198.12 | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 2,726 | $191.78 |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 935 | $175.99 |
| 73562 | <1% | 16 | $170.40 | |
| 80305 | <1% | 321 | $160.00 | |
| 87077 | <1% | 14 | $158.00 | |
| 83655 | <1% | 12 | $145.32 | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 366 | $144.48 |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 706 | $143.56 |
| 82728 | <1% | 200 | $135.66 | |
| 84484 | <1% | 1,880 | $133.71 | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 3,664 | $122.74 |
| 82607 | <1% | 24 | $90.91 | |
| J1171 | Injection, hydromorphone, 0.1 mg | <1% | 44 | $90.15 |
| 96127 | <1% | 26 | $89.88 | |
| 87430 | <1% | 279 | $79.60 | |
| 92552 | <1% | 14 | $76.17 | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 1,842 | $73.45 |
| 96376 | <1% | 92 | $70.34 | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 2,101 | $56.11 |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 2,679 | $52.84 |
| 84145 | <1% | 701 | $52.52 | |
| J0137 | Injection, acetaminophen (hikma), not therapeutically equivalent to j0131, 10 mg | <1% | 167 | $52.52 |
| Q9966 | Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml | <1% | 91 | $52.50 |
| 82140 | <1% | 231 | $46.75 | |
| 87040 | <1% | 377 | $42.56 | |
| J2003 | Injection, lidocaine hydrochloride, 1 mg | <1% | 38 | $36.00 |
| S0020 | Injection, bupivicaine hydrochloride, 30 ml | <1% | 302 | $32.11 |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 746 | $31.13 |
| 85007 | <1% | 46 | $26.75 | |
| 83540 | <1% | 12 | $26.54 | |
| 85379 | <1% | 300 | $20.92 | |
| 87070 | <1% | 14 | $16.30 | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 652 | $14.53 |
| J0136 | Injection, acetaminophen (b braun), not therapeutically equivalent to j0131, 10 mg | <1% | 38 | $14.52 |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | <1% | 454 | $12.68 |
| S0119 | Ondansetron, oral, 4 mg (for circumstances falling under the medicare statute, use hcpcs q code) | <1% | 52 | $8.61 |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 376 | $1.52 |
| J1596 | Injection, glycopyrrolate, 0.1 mg | <1% | 28 | $0.92 |
| J3475 | Injection, magnesium sulfate, per 500 mg | 0% | 85 | $0.00 |
| C1713 | Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) | 0% | 28 | $0.00 |
| 99080 | 0% | 135 | $0.00 | |
| J0134 | Injection, acetaminophen (fresenius kabi), not therapeutically equivalent to j0131, 10 mg | 0% | 29 | $0.00 |
| Q0177 | Hydroxyzine pamoate, 25 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | 0% | 13 | $0.00 |
| 87186 | 0% | 14 | $0.00 | |
| 83605 | 0% | 316 | $0.00 | |
| 92700 | 0% | 38 | $0.00 | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | 0% | 29 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialO'CONNOR, JAMES (PRESIDENT)
| Provider | Location | Paid |
|---|---|---|
| Pulmonary Associates of Lancaster, LTD | Lancaster, PA | $699K |
| Pediatric Associates of Cheshire PC | Cheshire, CT | $380K |
| Delaware Valley Residential Care LLC | Warminster, PA | $183K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.